The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly's rapid growth has been linked to its deep and varied roster of leading pharmaceutical products, including Trulicity and Mounjaro (treatments for diabetes) and Prozac and Cymbalta ...